Evaluating aerosol administration of a candidate TB vaccine MVA85A

Evaluating aerosol administration of a candidate TB vaccine MVA85A

Opis bibliograficzny
Główni autorzy:	Thomas, Z, Meyer, J, Harris, S, Satti, I, Sheehan, S, Bettinson, H, Mcshane, H
Format:	Journal article
Wydane:	2014

Podobne zapisy

Safety and immunogenicity of a candidate tuberculosis vaccine MVA85A delivered by aerosol in BCG-vaccinated healthy adults: a phase 1, double-blind, randomised controlled trial.
od: Satti, I, i wsp.
Wydane: (2014)

Safety and immunogenicity of a candidate tuberculosis vaccine MVA85A delivered by aerosol in BCG-vaccinated healthy adults: A phase 1, double-blind, randomised controlled trial
od: Satti, I, i wsp.
Wydane: (2014)

Phase I trial evaluating the safety and immunogenicity of candidate TB vaccine MVA85A, delivered by aerosol to healthy M.tb-infected adults
od: Riste, M, i wsp.
Wydane: (2021)

Comparing the safety and immunogenicity of a candidate TB vaccine MVA85A administered by intramuscular and intradermal delivery.
od: Meyer, J, i wsp.
Wydane: (2013)

Comparing the safety and immunogenicity of a candidate TB vaccine MVA85A administered by intramuscular and intradermal delivery
od: Meyer, J, i wsp.
Wydane: (2013)

Phase I Trial Evaluating the Safety and Immunogenicity of Candidate TB Vaccine MVA85A, Delivered by Aerosol to Healthy <em>M.tb</em>-Infected Adults
od: Michael Riste, i wsp.
Wydane: (2021-04-01)

Comparison of the safety and immunogenicity of a candidate TB vaccine, MVA85A, given by the intramuscular or intradermal route in BCG-vaccinated adults
od: Harris, S, i wsp.
Wydane: (2011)

A review of the tolerability of the candidate TB vaccine, MVA85A compared with BCG and Yellow Fever vaccines, and correlation between MVA85A vaccine reactogenicity and cellular immunogenicity
od: Rowland, R, i wsp.
Wydane: (2012)

Evaluation of a human BCG challenge model to assess antimycobacterial immunity induced by BCG and a candidate TB vaccine, MVA85A, alone and in combination
od: Harris, S, i wsp.
Wydane: (2013)

DEVELOPING A NEW TB VACCINE: BOOSTING BCG WITH MVA85A
od: Mcshane, H
Wydane: (2008)

The candidate TB vaccine, MVA85A, induces highly durable Th1 responses.
od: Tameris, M, i wsp.
Wydane: (2014)

The candidate TB vaccine, MVA85A, induces highly durable Th1 responses
od: Tameris, M, i wsp.
Wydane: (2014)

The candidate TB vaccine, MVA85A, induces highly durable Th1 responses.
od: Michele Tameris, i wsp.
Wydane: (2014-01-01)

Effect of vaccine dose on the safety and immunogenicity of a candidate TB vaccine, MVA85A, in BCG vaccinated UK adults.
od: Pathan, A, i wsp.
Wydane: (2012)

Effect of vaccine dose on the safety and immunogenicity of a candidate TB vaccine, MVA85A, in BCG vaccinated UK adults
od: Pathan, A, i wsp.
Wydane: (2012)

A Phase I study evaluating the safety and immunogenicity of MVA85A, a candidate TB vaccine, in HIV-infected adults
od: Minassian, A, i wsp.
Wydane: (2011)

Evaluation of the safety and immunogenicity of a candidate tuberculosis vaccine, MVA85A, delivered by aerosol to the lungs of macaques.
od: White, A, i wsp.
Wydane: (2013)

The effect of current Schistosoma mansoni infection on the immunogenicity of a candidate TB vaccine, MVA85A, in BCG-vaccinated adolescents: An open-label trial
od: Wajja, A, i wsp.
Wydane: (2017)

Evaluation of a human BCG challenge model to assess antimycobacterial immunity induced by BCG and a candidate tuberculosis vaccine, MVA85A, alone and in combination.
od: Harris, SA, i wsp.
Wydane: (2014)

Alternate aerosol and systemic immunisation with a recombinant viral vector for tuberculosis, MVA85A: A phase I randomised controlled trial
od: Manjaly Thomas, Z, i wsp.
Wydane: (2019)

Evaluating aerosol administration of a candidate TB vaccine, MVA85A, as a way to induce potent local cellular immune responses and avoid anti-vector immunity
od: Manjaly Thomas, ZR
Wydane: (2016)

Differential cytokine levels in adults induced by a Novel candidate TB boost vaccine, MVA85A-according to previous BCG vaccination status
od: Owiafe, P, i wsp.
Wydane: (2012)

Safety and immunogenicity of the candidate tuberculosis vaccine MVA85A in West Africa.
od: Brookes, R, i wsp.
Wydane: (2008)

The effect of current Schistosoma mansoni infection on the immunogenicity of a candidate TB vaccine, MVA85A, in BCG-vaccinated adolescents: An open-label trial.
od: Anne Wajja, i wsp.
Wydane: (2017-05-01)

A first-in-human phase 1 trial to evaluate the safety and immunogenicity of the candidate tuberculosis vaccine MVA85A-IMX313, administered to BCG-vaccinated adults.
od: Minhinnick, A, i wsp.
Wydane: (2016)

Boosting BCG with MVA85A: the first candidate subunit vaccine for tuberculosis in clinical trials.
od: Mcshane, H, i wsp.
Wydane: (2005)

Safety and immunogenicity of an FP9-vectored candidate tuberculosis vaccine (FP85A), alone and with candidate vaccine MVA85A in BCG-vaccinated healthy adults: a phase I clinical trial.
od: Rowland, R, i wsp.
Wydane: (2013)

Safety and immunogenicity of the candidate tuberculosis vaccine MVA85A in West Africa.
od: Roger H Brookes, i wsp.
Wydane: (2008-08-01)

A phase I trial evaluating the safety and immunogenicity of a candidate tuberculosis vaccination regimen, ChAdOx1 85A prime - MVA85A boost in healthy UK adults
od: Wilkie, M, i wsp.
Wydane: (2019)

Safety and immunogenicity of boosting BCG vaccinated subjects with BCG: comparison with boosting with a new TB vaccine, MVA85A.
od: Whelan, K, i wsp.
Wydane: (2009)

Correction: Safety and Immunogenicity of the Candidate Tuberculosis Vaccine MVA85A in West Africa.
od: Roger H. Brookes, i wsp.
Wydane: (2011-01-01)

Alternate aerosol and systemic immunisation with a recombinant viral vector for tuberculosis, MVA85A: A phase I randomised controlled trial.
od: Zita-Rose Manjaly Thomas, i wsp.
Wydane: (2019-04-01)

A Phase I, Open-Label Trial, Evaluating the Safety and Immunogenicity of Candidate Tuberculosis Vaccines AERAS-402 and MVA85A, Administered by Prime-Boost Regime in BCG-Vaccinated Healthy Adults
od: Sheehan, S, i wsp.
Wydane: (2015)

A new TB vaccine, MVA85A, induces durable antigen-specific responses 14 months after vaccination in African infants
od: Odutola, A, i wsp.
Wydane: (2012)

A new TB vaccine, MVA85A, induces durable antigen-specific responses 14 months after vaccination in African infants.
od: Odutola, A, i wsp.
Wydane: (2012)

Two doses of candidate TB vaccine MVA85A in antiretroviral therapy (ART) naive subjects gives comparable immunogenicity to one dose in ART+ subjects
od: Dieye, T, i wsp.
Wydane: (2013)

Effects of MVA85A vaccine on tuberculosis challenge in animals: systematic review
od: Mcshane, H, i wsp.
Wydane: (2016)

Process of Assay Selection and Optimization for the Study of Case and Control Samples from a Phase IIb Efficacy Trial of a Candidate Tuberculosis Vaccine, MVA85A
od: Harris, SA, i wsp.
Wydane: (2014)

Phase I/II clinical trial of MVA85A in individuals with latent tuberculosis: The first subunit TB vaccine in clinical trial
od: Sander, C, i wsp.
Wydane: (2005)

Correction: Safety and Immunogenicity of Boosting BCG Vaccinated Subjects with BCG: Comparison with Boosting with a New TB Vaccine, MVA85A.
od: Kathryn T. Whelan, i wsp.
Wydane: (2011-01-01)